Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | PPARD | Q03181 | 5/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476636 | 1.00 | S1PR1 (0.47) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL12477890 | 0.88 | S1PR1 (0.43) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL15327856 | 0.88 | S1PR1 (0.43) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL12477210 | 0.87 | S1PR1 (0.58) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL12477015 | 0.87 | S1PR1 (0.58) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL12477079 | 0.80 | PPARG (0.53) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL12476659 | 0.80 | PPARG (0.53) | S1PR1PPARGPPARAPPARDFFAR1 | |
| SCHEMBL12477044 | 0.80 | RORC (0.41) | S1PR1PPARGPPARAPPARD | |
| SCHEMBL12477040 | 0.80 | RORC (0.41) | S1PR1PPARGPPARAPPARD | |
| SCHEMBL12477187 | 0.79 | PPARG (0.47) | S1PR1PPARGPPARAPPARDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | claimed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | claimed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | claimed |
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | disclosed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | disclosed |
| EP-2658851-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Cadila Healthcare Limited (IN) | 2013-11-06 | — | — | EP | disclosed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | disclosed |
| WO-2012090220-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | LIPC, HMGCR, PCSK9 | S1PR1 1455/4885PPARG 161/4885PPARA 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.